Senior Bioinformatician / Senior Computational Biologist at Abata Therapeutics

Toronto, Ontario, Canada

Abata Therapeutics Logo
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

Candidates must possess an MS or PhD in bioinformatics, computational biology, or a related field, with at least 3 years of post-graduation experience, preferably in an industry setting. Essential qualifications include solid Python programming skills, experience working with large genomics data, particularly single-cell genomics data, and familiarity with Linux-based operating systems. Experience in an HPC environment, preferably AWS cloud, is also required. Desirable qualifications include familiarity with pipeline workflow languages like Metaflow or Snakemake, experience with containerization using Docker, and familiarity with R.

Responsibilities

The Senior Bioinformatician will be responsible for primary and secondary analysis of single-cell datasets, including read alignment and quality control. They will collaborate with wet-lab scientists to design experiments, troubleshoot data quality, and ensure smooth data handoff. This role involves developing data processing pipelines for single-cell sequencing and other high-throughput genomics assays, and partnering with software engineers to scale workflows in cloud environments. Responsibilities also include ensuring reproducibility through containerization and pipeline orchestration, and communicating results and insights to cross-functional teams. Staying current with advances in single-cell modalities and computational methods is also a key responsibility.

Skills

Python
Bioinformatics
Computational Biology
Linux
Single-cell genomics
HPC
AWS
R
Docker
Metaflow
Snakemake

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI